Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial

Menno R Germans1, René Post1, Bert A Coert1, Gabriël JE Rinkel2, W Peter Vandertop1 and Dagmar Verbaan1*

Abstract

Background: A frequent complication in patients with subarachnoid hemorrhage (SAH) is recurrent bleeding from the aneurysm. The risk is highest within the first 6 hours after the initial hemorrhage. Securing the aneurysm within this timeframe is difficult owing to logistical delays. The rate of recurrent bleeding can also be reduced by ultra-early administration of antifibrinolics, which probably improves functional outcome. The aim of this study is to investigate whether ultra-early and short-term administration of the antifibrinolytic agent tranexamic acid (TXA), as add-on to standard SAH management, leads to better functional outcome.

Methods/Design: This is a multicenter, prospective, randomized, open-label trial with blinded endpoint (PROBE) assessment. Adult patients with the diagnosis of non-traumatic SAH, as proven by computed tomography (CT) within 24 hours after the onset of headache, will be randomly assigned to the treatment group or the control group. Patients in the treatment group will receive standard treatment with the addition of a bolus of TXA (1 g intravenously) immediately after randomization, followed by continuous infusion of 1 g per 8 hours until the start of aneurysm treatment, or a maximum of 24 hours after the start of medication. Patients in the control group will receive standard treatment without TXA. The primary outcome measure is favorable functional outcome, defined as a score of 0 to 3 on the modified Rankin Scale (mRS), at 6 months after SAH. Primary outcome will be determined by a trial nurse blinded for treatment allocation. We aim to include 950 patients in 3 years.

Discussion: The strengths of this study are: 1. the ultra-early and short-term administration of TXA, resulting in a lower dose as compared to previous studies, which should reduce the risk for delayed cerebral ischemia (DCI), an important risk factor in the long-term treatment with antifibrinolics; 2. the power calculation is based on functional outcome and calculated with use of recent study results of our own population, supported by data from prominent studies; and 3. the participation of several specialized SAH centers, and their referring hospitals, in the Netherlands with comparative treatment protocols.

Trial registration: Nederlands Trial Register (Dutch Trial Registry) number NTR3272

Keywords: Neurosurgery, Subarachnoid hemorrhage, Early medical intervention, Tranexamic acid, Antifibrinolytic agents, Intracranial aneurysm, Functional outcome, Rebleeding

* Correspondence: D.Verbaan@amc.uva.nl
1Department of Neurosurgery, Neurosurgical Center Amsterdam, Academic Medical Center, PO Box 22660, 1100 DD, Amsterdam, the Netherlands
Full list of author information is available at the end of the article

© 2013 Germans et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Subarachnoid hemorrhage (SAH) from a ruptured aneurysm occurs in relatively young patients (mean age 55 years) and accounts for 5% of all strokes, with an incidence of approximately 9 per 100,000 person-years [1,2]. The case fatality rate is approximately 35%, 25% of the survivors have a favorable outcome, and only a small group recover completely [3]. A frequent complication in patients with a SAH is recurrent bleeding from the aneurysm, which happens primarily within the first few hours after the initial hemorrhage, and occurs in 10% to 22% of patients who present to a hospital [4-9]. Besides the primary hemorrhage, recurrent bleeding is still one of the major causes of death and disability [10].

Rebleeding can be prevented by early aneurysm occlusion, but in daily clinical practice treatment is often delayed by logistical factors, such as delay in diagnosis or transfer between hospitals [11-13] (own data, manuscript in preparation). Therefore, early aneurysm treatment alone is not sufficient to prevent all recurrent bleedings and other strategies have to be explored. An alternative to reduce the risk of rebleeding is the administration of an antifibrinolytic agent, which slows the breakdown of the blood clot, prior to aneurysm occlusion [14]. Long-term administration of antifibrinolytics has been found to effectively reduce the risk of recurrent bleeding by approximately 40%, but patient outcome does not improve owing to a concurrent increase in delayed cerebral ischemia (DCI) [14]. Recent studies using early and short-term antifibrinolytic therapy have also shown reduction of recurrent rebleeding but without an increase in DCI [7,8,14,15]. However, the only randomized controlled trial (RCT) that was performed was underpowered to show an effect on functional outcome [7].

The aim of this RCT is to investigate whether treatment with ultra-early and short-term administration of the antifibrinolytic agent tranexamic acid (TXA), as add-on to standard, state-of-the-art SAH management, leads to a significantly higher percentage of patients with a favorable functional outcome, defined as a score of 0 to 3 on the modified Rankin Scale (mRS), assessed at 6 months after SAH.

Methods/Design
Design
The ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA) study will be performed as a multicenter, prospective, randomized, open-label trial with blinded endpoint (PROBE) assessment.

Setting
The protocol of this study was approved by the Medical Ethics Committee (MEC) of the Academic Medical Center (AMC), Amsterdam, the Netherlands. It is registered at the Nederlands Trial Register (Dutch Trial Registry), number NTR3272. At the start of the study at 15 May 2013, a total of 26 participating hospitals, including three specialized SAH centers (study centers) and their referring hospitals, will start randomization for the ULTRA study. It is expected that four additional study centers and their referring hospitals will start randomization in the near future.

Participants
All patients presenting with a proven SAH will be checked for eligibility by the treating physician. Inclusion criteria are: adult patients (≥18 years) with the diagnosis of SAH, as proven by CT within 24 hours after the last hemorrhage. Exclusion criteria are: 1. no loss of consciousness after the hemorrhage, with World Federation of Neurological Surgeons (WFNS) grade 1 or 2 on admission in combination with a perimesencephalic bleeding pattern; 2. history and bleeding pattern on CT compatible with a traumatic SAH; 3. ongoing treatment for deep vein thrombosis or pulmonary embolism; 4. history of a hypercoagulability disorder; 5. pregnancy; 6. severe renal (serum creatinine >150 mmol/l) or liver (aspartate aminotransferase (AST) >150 U/l or alanine aminotransferase (ALT) >150 U/l or alkaline phosphatase (ALP) >150 U/l or gamma-glutamyltransferase (γ-GT) >150 U/l) failure; 7. expected death within 24 hours; and 8. participation in another SAH intervention study.

Randomization
Online randomization will be performed by the treating physician in the study center using permuted blocks and with stratification by study center, to ensure an equal number of patients in both study arms at each study center.

Interventions
All participating patients will be treated according to state-of-the-art SAH management, comparable with recent published international guidelines [2,16]. Subjects with CT-confirmed SAH who are randomly assigned to the treatment group will receive additional administration of TXA. This treatment consists of a bolus of TXA (1 g intravenously) as soon as possible after randomization (also at the referring hospital when applicable), followed by continuous infusion of 1 g per 8 hours, until a maximum of 24 hours after the start of medication. If aneurysm treatment is initiated within 24 hours after the TXA bolus, the medication infusion will be discontinued at the time-out procedure before start of the aneurysm treatment (endovascular or surgical). The continuous infusion of the study medication will be cancelled immediately if, after inclusion: 1. no aneurysm appears to be present on CT angiography (CTA) and/or digital subtraction angiography.
angiography (DSA); 2. other intracranial pathology than an aneurysm is responsible for the SAH; or 3. the aneurysm which is visualized is not held responsible for the hemorrhage, based on the bleeding pattern on CT. Patients randomly assigned to the control group will not receive TXA treatment. The procedures performed during the study are outlined in Figure 1.

Consent procedure
This study evaluates the impact of a treatment initiated as soon as possible in an emergency situation. Since the majority of patients will not be able to give informed consent at admission, the informed consent procedure for this study will be delayed in a so-called emergency procedure. For patients who are randomized for TXA administration, the medication will be administrated as soon as possible after randomization. Information about the study will be given to the patients or their legal representatives as soon as possible in the study center. Patients or their legal representatives will be asked about participation in the study by signing an informed consent. If patients or legal representatives decline to participate, study medication will be stopped immediately (if randomized for treatment and TXA is still administered) and the patient will be excluded from the study.

Primary outcome
The primary endpoint, defined as a favorable functional outcome on the mRS (score 0 to 3) [17], will be assessed at 6 months after the SAH by a trial nurse who is blinded for treatment allocation during a standardized, validated telephone interview [18].

Secondary outcomes
Secondary outcome measures are: case fatality rate, cause of poor outcome, rebleeding rate, complication rate (including delayed ischemic stroke, thromboembolic events, hydrocephalus, extracranial thrombosis, or hemorrhagic complications), discharge location, (micro)infarctions on magnetic resonance (MR) imaging at 6 months after endovascular treatment, quality of life at 6 months after SAH (with EQ-5D questionnaire (EuroQol Group, Rotterdam, the Netherlands) [19]), and healthcare use and healthcare-related costs until 6 months after SAH.

Figure 1 Flow chart of procedures.
Sample size calculation
The primary endpoint analysis of this study is based on the difference in percentage of patients with favorable outcome (mRS score 0 to 3) at 6 months after SAH between patients with and without TXA treatment. This expected difference between the TXA and control group was estimated with the results of renowned SAH studies and our own data (293 consecutive aneurysmal SAH patients, added with angiogram-negative SAH patients, treated at the AMC between 2008 and 2011). The percentage of SAH patients (including angiogram-negative patients) who reach the hospital have a favorable outcome of 69% (own data) and the rebleeding rate is 17%, which is consistent with numbers reported in previous studies (11% to 22%) [6-8]. For patients with recurrent bleeding, an estimated 20% will have a favorable outcome (0.17 \times 0.20 = 3.4\% of the total control group). Consequently, the percentage of patients with a favorable outcome without recurrent bleeding is 79% (total of patients without recurrent bleeding with a favorable outcome: 69 - 3.4 = 65.6\%; total of patients without recurrent bleeding: 100 - 17 = 83\%; 65.6 / 83 = 0.79).

In the TXA group, the reduction in recurrent bleeding is expected to be 77\% [7,8], which reduces the rate of rebleeding to 3.9\% (0.17 \times 0.77 = 13.1\%; 17\% - 13.1\% = 3.9\%). Furthermore, TXA is anticipated to improve the percentage of favorable outcome in patients with recurrent bleeding from 20\% to 30\% [7]. Therefore, in the TXA group, 3.9\% will have recurrent bleeding, of which 30\% will have a favorable outcome (0.039 \times 0.3 = 1.2\% of the total TXA group). Patients without recurrent bleeding will have a favorable outcome of 79\%, which is 75.9\% of the total TXA group (total of patients without recurrent bleeding: 100 - 3.9 = 96.1; 0.961 \times 0.79 = 75.9\%). In the TXA group, the total of patients with a favorable outcome is 77.1\% (75.9\% + 1.2\%). Based on these assumptions, it is expected that TXA administration will increase the proportion of patients with a favorable outcome from 69\% to 77.1\%. A two-group chi-square test with a 0.05 two-sided significance level will have 80\% power to detect the difference between a control group proportion of 0.69 and a treatment group proportion of 0.771 (odds ratio of 1.513) when the sample size in each group is 470 (940 patients in total). The plan is to include a total of 950 patients. The aim is to include these patients within 3 years. Analysis of the results is planned in 2016.

Statistical analysis
The statistical analysis will be by intention-to-treat. The occurrence of the primary outcome, mRS score 0 to 3 at 6 months, will be compared between the two randomization groups. The secondary outcome analyses will compare the above described variables between randomization groups. Subgroup analyses will be performed to evaluate whether the rate of recurrent bleeding and percentage of favorable outcome differ between gender and groups with different WFNS grade at admission. Subsequently, the association between favorable outcome and time interval from the last hemorrhage to first TXA administration will be evaluated. Group differences for continuous variables will be calculated using an independent t-test for continuous variables with a parametric distribution or Mann-Whitney U test for continuous variables with a non-parametric distribution. Group differences for categorical variables will be calculated using chi-square statistics. Chi-square statistics will be used to calculate an odds ratio, risk ratio or risk difference. Adjustments for factors that differ at randomization will be made using regression or multi-level models. A P value < 0.05 will be considered significant.

For the cost-effectiveness analysis, the mRS score at 6 months is the effect measure. The costs during admission and the costs from discharge to 6 months after SAH will be summed up, resulting in one value for overall direct and indirect costs. The incremental cost-effectiveness ratio and its 95\% confidence interval (CI) will be estimated with bootstrapping.

Data safety analysis
An interim analysis will be performed by a Data and Safety Monitoring Board (DSMB) when half of the patients (n = 475) are enrolled. In this analysis unblinded data are assessed and the DSMB can advise to adjust the conduct, design or sample size, or to terminate the study according to predefined stopping rules. These rules are: 1. clear evidence that TXA administration is harmful for patients; or 2. superiority in functional outcome (mRS 0 to 3) in the treatment group after 6 months, evaluated with the Peto analysis [20] with a P value of 0.001.

Discussion
Antifibrinolytic therapy after aneurysmal SAH reduces rebleeding by approximately 40\% [14], but outcome is not improved owing to a concurrent increase in DCI. Recent studies of early, short-term antifibrinolytic therapy have shown better results, with a tendency for improved functional outcome, but were judged to be biased and, in case of the only RCT, underpowered [7,8,15]. These results raise the expectation that a reduction of rebleeding without an increase of DCI will improve functional outcome at 6 months. We have developed an RCT for ultra-early and short-term treatment with TXA, with the sample size calculation based on the expected improvement in functional outcome.

Our study has several strengths. TXA can be administered as soon as possible after randomization since the emergency procedure for delayed informed consent is used in this study, and the risk of DCI is reduced to a
minimum by the short-term and low total dose of TXA. In addition, our dosing regimen is considered safe because the maximum dose is lower than in previous studies and the administration regimen is in concordance with the CRASH-2 trial [21]; the power calculation is based on functional outcome and calculated with use of recent study results of our own population, supported by data from prominent studies; a significant proportion of the ten specialized SAH centers throughout the Netherlands, including their referring hospitals, are willing to participate; and both coordinating centers (AMC and University Medical Center Utrecht (UMCU), the Netherlands) are experienced in coordinating clinical trials in SAH.

There are some limitations of our protocol. First, patients and personnel are not blinded for treatment allocation, which could potentially lead to a detection bias. However, owing to the PROBE design, the assessor of the primary endpoint is blinded for treatment allocation, which prevents detection bias. Second, the maximum duration of TXA administration will be 24 hours. Theoretically, this could be too short for patients who are treated later than 24 hours after the diagnosis. However, the risk of rebleeding is strongly decreased after 24 hours [6] and the antifibrinolytic function of TXA in blood serum remains for 7 to 8 hours when several doses have been given. In addition, our own data (not shown) show that 74% of patients are treated within 24 hours, with a median time of 18 hours. Therefore, with the early aneurysm treatment, low risk of rebleeding after 24 hours and remaining antifibrinolytic function, we expect to expose patients to a minimal risk of rebleeding when terminating TXA therapy after a maximum of 24 hours.

In conclusion, we have developed a protocol for a randomized, open-label study with administration of TXA in SAH patients. In contrast with earlier studies, the treatment will start ultra-early to reduce as many recurrent bleedings as possible and treatment will be continued to a maximum of 24 hours to prevent an increase in DCI. Since functional outcome assessed at 6 months is taken as the primary endpoint, this study will provide an answer for whether an increase of favorable outcome can be reached in patients with ultra-early and short-term TXA treatment after SAH.

Roles and responsibilities
Principal investigator and executive team
D Verbaan is the principal investigator (PI) and will coordinate the trial. D Verbaan is responsible for preparation of protocols and questionnaires, recruiting centers and funding, MEC application, day-to-day conduct of the trial, supplying information about the trial, statistical validity, and publication of the results. MR Germans is responsible for preparation of protocols and questionnaires, recruiting funding, MEC application, evaluating cause of unfavorable outcome, data analysis, writing, and publication of the results. BA Coert is responsible for recruiting centers, medical support in day-to-day conduct of the trial, evaluating cause of unfavorable outcome, and publication of the results. R Post is responsible for recruiting centers, day-to-day conduct of the trial, trial database, communicating and writing information to centers, preparing DSMB and annual reports, data analysis, writing, and publication of the results. Prof WP Vandertop is the PI at the AMC and VU University Medical Center (VUMC), the Netherlands, and is responsible for evaluating cause of unfavorable outcome, and publication of the results. Prof GJE Rinkel is PI at the UMCU. NM Fleitour is responsible for entering data in the trial database, coordinating all correspondence, and sending postal questionnaires and reminders. YK Bartels will perform the telephone interview for outcome assessment at 6 months.

Trial committees
Executive committee
D Verbaan, PhD (PI, AMC); MR Germans, MD (study coordinator (SC), AMC); BA Coert, MD, PhD (SC, AMC); R Post, MD (SC, AMC); Prof WP Vandertop, MD (PI, AMC, VUMC); Prof GJE Rinkel, MD (PI, UMCU); NM Fleitour (trial nurse); and YK Bartels (outcome assessor).

Steering committee
D Verbaan, clinical epidemiologist (AMC); MR Germans, neurosurgeon (AMC); BA Coert, neurosurgeon (AMC); R Post, resident neurosurgery (AMC); Prof WP Vandertop, neurosurgeon (AMC, VUMC); YBWEM Roos, neurologist (AMC); R van den Berg, neuroradiologist (AMC); Prof CBLM Majoie, neuroradiologist (AMC); J Horn, neurointensivist (AMC); and Prof GJE Rinkel, neurologist (UMCU). New members may be added if more centers join the study.

Data and Safety Monitoring Board
Prof BMJ Uitdehaag, clinical neuroepidemiologist (VUMC); Prof ARJ Girbes, intensivist (VUMC); and N van Geloven, statistician (AMC).

Statistical analysis
D Verbaan, clinical epidemiologist (AMC); MR Germans, neurosurgeon (AMC); R Post, resident neurosurgery (AMC); and Prof RJ de Haan, clinical epidemiologist (AMC).

Trial status
The study start date is 15 May 2013. The estimated study duration will be 3 years.
This project is funded by Fonds NutsOhra (project number 1202).

Funding

PI in two of the study centers. DV is PI, developed the conception and design of the study, critically revised the manuscript, and is PI in one of the initiating study centers. WPV participated in the conception and design of the study, critically revised the manuscript, and is PI in two of the study centers. DV is PI, developed the conception and design of the study, and critically revised the manuscript. All authors read and approved the final manuscript.

Competing interest

The authors declare that they have no competing interests.

Authors’ contributions

MRG developed the conception and design of the study, and drafted the manuscript. GJER participated in the conception and design of the study, and drafted the manuscript. RP and BAC critically revised the manuscript. GJER participated in the conception and design of the study, critically revised the manuscript, and is PI in one of the initiating study centers. WPV participated in the conception and design of the study, critically revised the manuscript, and is PI in two of the study centers. DV is PI, developed the conception and design of the study, and critically revised the manuscript. All authors read and approved the final manuscript.

Abbreviations

ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AMC: Academic Medical Center; AST: Aspartate aminotransferase; CI: Confidence interval; CT: Computed tomography; CTA: Computed tomography angiography; DCI: Delayed cerebral ischemia; DSA: Digital subtraction angiography; DSIB: Data and Safety Monitoring Board; ME: Medical Ethics Committee; MR: Magnetic resonance; mRS: Modified Rankin Scale; PI: Principal investigator; PROBE: Prospective randomized, open-label, blinded endpoint; RCT: Randomized controlled trial; SAH: Subarachnoid hemorrhage; SC: Study coordinator; TXA: Tranexamic acid; ULTRA: Ultra-early tranexamic acid after subarachnoid hemorrhage; UMCU: University Medical Center Utrecht; VU/MC: VU University Medical Center; WFNS: World Federation of Neurological Surgeons; y-GT: Gamma-glutamyltranspeptidase.

References

1. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ: Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007, 78:1365–1372.
2. Steiner T, Jovela S, Unterberg A, Jung C, Forsting M, Rinkel G: European stroke organization guidelines for the management of intracranial aneurysms and subarachnoid hemorrhage. Cerebrovasc Dis 2013, 35:93–112.
3. Wermer MJ, Kool H, Albrecht KW, Rinkel GJ: Subarachnoid hemorrhage treated with clipping: long-term effects on employment, relationships, personality, and mood. Neurosurgery 2007, 60:91–97.
4. Beck J, Raabe A, Szelényi A, Berkefeld J, Gerlach R, Setzer M, Siefert V: Sentinel headache and the risk of rebleeding after aneurysmal subarachnoid hemorrhage. Stroke 2006, 37:2733–2737.
5. Brismar JL, Song JK, Newell DW: Cerebral aneurysms. N Engl J Med 2006, 355:928–939.
6. Guo LM, Zhou HY, Xu JW, Wang Y, Qiu YM, Jiang JY: Risk factors related to aneurysmal rebleeding. World Neurosurg 2011, 76:292–298.
7. Hillman J, Fridriksson S, Nilsson G, Yu Z, Savoldi H, Jakobsson KE: Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg 2002, 97:771–778.
8. Starke RM, Kim GH, Fernandez A, Komotor RJ, Hickman ZL, Otten ML, Ducruet AF, Kellerer C, Hahn DK, Chwajol M, Mayer SA, Connolly ES Jr: Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 2008, 39:2617–2621.
9. Starke RM, Connolly ES Jr: Rebleeding after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011, 15:241–246.
10. Roos YB, Beenen LF, Groen RJ, Albrecht KW, Vermeulen M: Timing of surgery in patients with aneurysmal subarachnoid hemorrhage: rebleeding is still the major cause of poor outcome in neurosurgical units that aim at early surgery. J Neurol Neurosurg Psychiatry 1997, 63:490–493.
11. Laidlaw JD, Siu KH: Ultra-early surgery for aneurysmal subarachnoid hemorrhage: outcomes for a consecutive series of 391 patients not selected by grade or age. J Neurosurg 2002, 97:250–258.
12. Phillips TJ, Dowling RJ, Yan B, Laidlaw JD, Mitchell PJ: Does treatment of ruptured intracranial aneurysms within 24 hours improve clinical outcome? Stroke 2011, 42:1936–1945.
13. Lamb JN,ocker M, Tait MJ, Anthony BB, Papadopoulos MC: Delays in treating patients with good grade subarachnoid haemorrhage in London. Br J Neurosurg 2011, 25:239–248.
14. Roos YB, Rinkel GJ, Vermeulen M, Algra A, Van GJ: Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage. Cochrane Database Syst Rev 2003, 2:CD001245.
15. Gaberel T, Magheru C, Emery E, Derlon JM: Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis. Acta Neurochir (Wien) 2012, 154:1–9.
16. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, D'ion J, Higashida RT, Hoh BL, Kirkness CJ, Naidech AM, Ogilvy CS, Patel AB, Thompson BG, Vespa P, American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012, 43:1711–1737.
17. Rankin J: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957, 2:200–215.
18. Janssen PM, Visser NA, DorhoutMees SM, Nlijn CJ, Algra A, Rinkel GJ: Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis 2010, 29:137–139.
19. Ronne-Engstrom E, Enblad P, Lundstrom E: Outcome after spontaneous subarachnoid hemorrhage measured with the EQ-5D. Stroke 2011, 42:3284–3286.
20. Schulz KF, Grimes DA: Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 2005, 365:1567–1566.
21. Roberts I, Perel P, Prieto-Merino D, Shaker H, Coats T, Hunt BJ, Lecky F, Brohi K, Willett K: Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ 2012, 345:e5839.

Cite this article as: Germans et al.: Ultra-early tranexamic acid after subarachnoid hemorrhage (ULTRA): study protocol for a randomized controlled trial. Trials 2013;14:143.